MGI Launches Overseas Production Line of DNBSEQ-G400* Sequencer in Latvia

In a significant move that further solidifies its commitment to advancing life science technology, MGI Tech Co., Ltd. ("MGI") is proud to announce the launch of its overseas production line in Latvia. Under the subsidiary name LATVIA MGI TECH, SIA ("MGI Latvia"), the company has established a large-scale facility in Riga to assemble and produce the state-of-the-art DNBSEQ-G400* gene sequencing instruments and Sequencing reagents. This strategic expansion marks a significant milestone for MGI's growth in Europe, enabling the company to provide cutting-edge solutions for its customers and partners in the region.

MGI's Expansion in Europe

Europe has always been at the forefront of technology and innovation, making it a key market for MGI. By launching its production line in Latvia, MGI aims to leverage the region's technological prowess and establish a strong foothold in Europe's life science sector. The facility in Riga will serve as MGI's largest regional hub in Europe, enabling efficient production, assembly, and distribution of the DNBSEQ-G400* sequencers and HotMPS** reagents.

A Milestone Achievement

During the official opening ceremony, MGI unveiled the first DNBSEQ-G400* instrument produced at the Latvia site. This momentous occasion represents a significant step forward for MGI's European business development. As the company gradually increases its production capacity, a dedicated team of engineers in Latvia will provide ongoing support for production and quality control. Additionally, MGI Latvia will offer comprehensive aftersales support and maintenance services to ensure the seamless operation of the sequencing instruments.

MGI Latvia's Contributions to Research and Development

Since its establishment in 2019, MGI Latvia has emerged as a dynamic hub for research and development, production, logistics, and specialized training. With a remarkable investment exceeding 20 million euros, MGI Latvia is the largest foreign investment in the biotechnology sector in Latvia and the Baltics to date. The facility spans 7,000 square meters and features a Global Product Application Demo Centre and a state-of-the-art Customer Experience Center, which opened last year to showcase MGI's latest technologies. In addition to production activities, MGI Latvia has successfully collaborated with local and regional partners on numerous funded research programs, including Horizon 2020.

DNBSEQ-G400*: Advancing DNA Sequencing Technology

The DNBSEQ-G400* is a versatile, medium throughput benchtop sequencer that empowers researchers with its flexible sequencing modes. With its new Flow Cell system, the G400* enables users to run one or two flow cells, offering various read length options from SE50 to SE400 or PE300. The instrument incorporates optimized optical and biochemical systems, accelerating the sequencing process and delivering a streamlined user experience.

Designed specifically for use with the DNBSEQ-G400*, the innovative sequencing chemistry complements commonly used library preparation methods. Leveraging MGI's core DNBSEQ™ technology and the combinatorial Probe Anchor Synthesis (cPAS) technology, achieves breakthroughs in nucleotides and enzymes used in the sequencing process. This cutting-edge chemistry ensures low error rates, minimal duplication, and negligible index hopping, enhancing the accuracy and reliability of sequencing results.

• MGI Tech Co., Ltd. establishes an overseas production line in Latvia for the assembly of DNBSEQ-G400* gene sequencing instruments and Sequencing reagents.

• The facility in Riga, Latvia, serves as MGI's largest regional hub in Europe and enables efficient production, assembly, and distribution of the advanced sequencing technology.

• The launch of the production line marks a significant step in MGI's European business development, expanding its capacity to provide cutting-edge solutions and support for customers and partners in the region.

Conclusion

MGI's launch of its overseas production line in Latvia represents a significant milestone in the company's mission to advance life science tools and technologies. By expanding its presence in Europe, MGI is well-positioned to serve its customers and partners with real-time, comprehensive, and innovative solutions. The establishment of the Latvia facility, alongside the production of the DNBSEQ-G400* sequencers and sequencing reagents, underscores MGI's dedication to driving scientific innovation in DNA sequencing. As demand for advanced genomic solutions continues to grow, MGI remains committed to expanding its production capacity and enhancing its presence in Europe to meet the evolving needs of the scientific community.

• Unless otherwise informed, StandardMPS and CoolMPS sequencing reagents, and sequencers for use with such reagents are not available in Germany, Spain, UK, Sweden, Italy, Czech Republic, Switzerland, and Hong Kong (CoolMPS is available in Hong Kong).

• For Research Use Only. Not for use in diagnostic procedures (except as specifically noted).
  ** This sequencing reagent is only available in selected countries.

About MGI

MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.

MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.

The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.

For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.